Tumor-specific TCR-T cells (Guangzhou FineImmune Biotechnology)

N/A

Report date: 2024/11/26 16:13:28

Base Information

Drug NameTumor-specific TCR-T cells (Guangzhou FineImmune Biotechnology)
Drug Alias NameFIT-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Fineimmune Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Fineimmune Biotechnology
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A